News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Meltz Mark A
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/05/2023 |
4
| Meltz Mark A (COO General Counsel Secretary) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Paid exercise price by delivering 541 shares
@ $4.3, valued at
$2.3k
|
|
| 02/14/2023 |
4
| Meltz Mark A (COO General Counsel Secretary) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Granted 215,000 options to buy
@ $6.78, valued at
$1.5M
|
|
| 12/02/2022 |
4
| Meltz Mark A (COO General Counsel Secretary) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Paid exercise price by delivering 541 shares
@ $7.75, valued at
$4.2k
|
|
| 09/02/2022 |
4
| Meltz Mark A (COO General Counsel Secretary) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Granted 25,000 shares
@ $0 |
|
| 02/15/2022 |
4
| Meltz Mark A (COO General Counsel Treasurer) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Granted 135,000 options to buy
@ $10.03, valued at
$1.4M
|
|
| 02/16/2021 |
4
| Meltz Mark A (COO General Counsel Treasurer) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Granted 100,000 options to buy
@ $35.38, valued at
$3.5M
|
|
| 12/02/2020 |
3
| Meltz Mark A (COO General Counsel Treasurer) has filed a Form 3 on Kinnate Biopharma Inc. |
| 01/15/2020 |
4
| Meltz Mark A (SVP, General Counsel) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 32,705 shares
@ $60, valued at
$2M
Disposed/sold 104,000 options to buy
@ $37.26, valued at
$3.9M
|
|
| 12/16/2019 |
4
| Meltz Mark A (SVP, General Counsel) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 4,628 shares
@ $59.37, valued at
$274.8k
|
|
| 04/01/2019 |
4
| Meltz Mark A (SVP, General Counsel) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Granted 37,333 shares
@ $0
Granted 104,000 options to buy
@ $37.26, valued at
$3.9M
|
|
| 04/01/2019 |
3
| Meltz Mark A (SVP, General Counsel) has filed a Form 3 on Audentes Therapeutics, Inc. |
|
|